Current Oncology - McMaster Experts

publication venue for

Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference 2022
Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma 2011
Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer 2011
Current management of castrate-resistant prostate cancer 2010
The 4th Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake 2009
The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake 2008
Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada.. 32:346. 2025
Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).. 32:319. 2025
The Design of a Patient-Centered Hierarchal Composite Outcome for a Multi-Center Randomized Controlled Trial in Metastatic Bone Disease.. 32:318. 2025
18F-FDG PET/CT Semiquantitative and Radiomic Features for Assessing Pathologic Axillary Lymph Node Status in Clinical Stage I-III Breast Cancer Patients: A Systematic Review.. 32:300. 2025
Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer: A Systematic Review.. 32:231. 2025
When "One Size Fits All" Fits None: A Commentary on the Impacts of the"Draft Canadian Breast Cancer Screening Guidelines" on Racialized Populations in Canada.. 32:123. 2025
Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma.. 32:118. 2025
A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline-Taxane Chemotherapy in Early HER-2 Negative Breast Cancer.. 32:6. 2024
Management of Ductal Carcinoma In Situ: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.. 31:7738-7753. 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer.. 31:7226-7243. 2024
Oncology Camp Participation and Psychosocial Health in Children Who Have Lived with Cancer-A Pilot Study.. 31:7165-7176. 2024
Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum.. 31:6979-6999. 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.. 31:6536-6567. 2024
Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process.. 31:6512-6535. 2024
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors.. 31:6356-6383. 2024
Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective.. 31:6017-6031. 2024
Simplifying Serious Illness Communication: Preparing or Deciding.. 31:5832-5837. 2024
Biopsychosocial Associates of Psychological Distress and Post-Traumatic Growth among Canadian Cancer Patients during the COVID-19 Pandemic.. 31:5354-5366. 2024
Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.. 31:4704-4712. 2024
Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario. 31:4656-4674. 2024
A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer. 31:4531-4545. 2024
The Omission of Anthracycline Chemotherapy in Women with Early HER2-Negative Breast Cancer—A Systematic Review and Meta-Analysis. 31:4486-4506. 2024
HPV Self-Sampling for Cervical Cancer Screening in Under-Screened Saskatchewan Populations: A Pilot Study. 31:4261-4269. 2024
Canadian Consensus for Treatment of BRAF V600E Mutated Pediatric and AYA Gliomas. 31:4022-4029. 2024
Survival Outcomes for US and Canadian Patients Diagnosed with Hodgkin Lymphoma before and after Brentuximab Vedotin Approval for Relapsed/Refractory Disease: A Retrospective Cohort Study. 31:3885-3894. 2024
The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities. 31:3826-3844. 2024
Patient and Provider Attitudes and Preferences Regarding Early Palliative Care Delivery for Patients with Advanced Gastrointestinal Cancers: A Prospective Survey. 31:3329-3341. 2024
Oncologists’ Satisfaction with Virtual Care: A Questionnaire. 31:3269-3277. 2024
Mother-Child Approach to Cervical Cancer Prevention in a Low Resource Setting: The Cameroon Baptist Convention Health Services Story.. 31:3227-3238. 2024
Abstracts of the Cell Therapy Transplant Canada 2023 Annual Conference. 31:2918-2951. 2024
Patient and Family Financial Burden in Cancer: A Focus on Differences across Four Provinces, and Reduced Spending Including Decisions to Forego Care in Canada. 31:2713-2726. 2024
The Significance of Thyroid Hormone Receptors in Breast Cancer: A Hypothesis-Generating Narrative Review. 31:2364-2375. 2024
Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement. 31:1803-1816. 2024
Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development. 31:1426-1444. 2024
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice. 31:1400-1415. 2024
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care. 31:1376-1388. 2024
Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study. 31:1278-1290. 2024
Sex-Based Analysis of Quality Indicators of End-of-Life Care in Gastrointestinal Malignancies. 31:1170-1182. 2024
Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use. 31:425-435. 2024
Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response. 31:1-23. 2023
Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective. 30:10477-10487. 2023
Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease. 30:9514-9529. 2023
Fractionated Stereotactic Radiation for Central Nervous System Lymphoma: Retrospective Analysis of Initial Cases. 30:8602-8611. 2023
Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology—A National Questionnaire. 30:7627-7637. 2023
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer. 30:7384-7397. 2023
Perceptions of Cancer in Parents of Adolescent Daughters in Northwest Cameroon. 30:7167-7177. 2023
The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review. 30:6976-6985. 2023
Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data. 30:6596-6608. 2023
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. 30:6559-6574. 2023
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. 30:6473-6496. 2023
Association between COPD and Stage of Lung Cancer Diagnosis: A Population-Based Study. 30:6397-6410. 2023
Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer. 30:6289-6315. 2023
Preoperative Breast Magnetic Resonance Imaging: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. 30:6255-6270. 2023
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey. 30:6166-6176. 2023
Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations. 30:5652-5679. 2023
Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective. 30:4688-4699. 2023
Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition. 30:4527-4537. 2023
Consensus Recommendations to Optimize the Detection and Reporting of NTRK Gene Fusions by RNA-Based Next-Generation Sequencing. 30:3989-3997. 2023
Implementation of a Web-Based Communication System for Primary Care Providers and Cancer Specialists. 30:3537-3548. 2023
Safety and Accuracy of Sentinel Lymph Node Biopsy Alone in Clinically Node-Positive Patients Undergoing Upfront Surgery for Invasive Breast Cancer: A Systematic Review. 30:3102-3110. 2023
Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force. 30:3079-3090. 2023
Optimizing Cancer Survivorship Care: Examination of Factors Associated with Transition to Primary Care. 30:2743-2750. 2023
Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study. 30:1977-1985. 2023
Societal Perspectives and Real-World Cost-Effectiveness: Expanding the Scope of Health Economics Inquiry. 30:233-235. 2022
A Survey-Based Study on Physical Activity Promotion for Individuals with a Current or Past Diagnosis of Cancer in Canada. 29:9801-9812. 2022
Experiences and Lessons Learned from Implementing the RELIEF Digital Symptom Self-Reporting App in a Palliative Home Care Setting. 29:9401-9406. 2022
Implementation of a Routine Screening Program for Latent Tuberculosis Infection among Patients with Acute Leukemia at a Canadian Cancer Center. 29:9325-9334. 2022
Quality of End-of-Life Care in Gastrointestinal Cancers: A 13-Year Population-Based Retrospective Analysis in Ontario, Canada. 29:9163-9171. 2022
Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. 29:9046-9065. 2022
Patient and Healthcare Provider Perspectives on the Implementation of a Web-Based Clinical Communication System for Cancer: A Qualitative Study. 29:8401-8414. 2022
Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients. 29:7953-7963. 2022
Clinical Management of Financial Toxicity–Identifying Opportunities through Experiential Insights of Cancer Survivors, Caregivers, and Social Workers. 29:7705-7717. 2022
Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia. 29:7624-7636. 2022
Predictors of Functional Recovery among Musculoskeletal Oncology Patients Undergoing Lower Extremity Endoprosthetic Reconstruction. 29:7598-7606. 2022
Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy. 29:6794-6806. 2022
Confronting the Negative Impact of Cigarette Smoking on Cancer Surgery. 29:5869-5874. 2022
Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned. 29:5616-5626. 2022
Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma. 29:5426-5441. 2022
Identifying Breast Cancer Recurrence in Administrative Data: Algorithm Development and Validation. 29:5338-5367. 2022
Emerging Biomarker-Guided Therapies in Prostate Cancer. 29:5054-5076. 2022
Risk Stratification and Cancer Follow-Up: Towards More Personalized Post-Treatment Care in Canada. 29:3215-3223. 2022
Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. 29:2599-2615. 2022
Linking Intermediate to Final “Real-World” Outcomes: Is Financial Toxicity a Reliable Predictor of Poorer Outcomes in Cancer?. 29:2483-2489. 2022
Report from the Ready for the Next Round Thought-Leadership Roundtables on Building Resilience in Cancer Care and Control in Canada-Colorectal Cancer Canada; 2021. 29:1723-1743. 2022
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. 29:1575-1582. 2022
The Serious Illness Care Program in Oncology: Evidence, Real-World Implementation and Ongoing Barriers. 29:1527-1536. 2022
Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma. 29:1501-1513. 2022
An Evidence-Based Guideline for Surveillance of Patients after Curative Treatment for Colon and Rectal Cancer. 29:724-740. 2022
Models of Follow-Up Care and Secondary Prevention Measures for Survivors of Colorectal Cancer: Evidence-Based Guidelines and Systematic Review. 29:439-454. 2022
Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline. 29:231-242. 2022
Understanding the Attitudes and Beliefs of Oncologists Regarding the Transitioning and Sharing of Survivorship Care. 28:5452-5465. 2021
Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus. 28:5434-5451. 2021
A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. 28:5073-5083. 2021
Stakeholder-Identified Interventions to Address Cancer Survivors’ Psychosocial Needs after Completing Treatment. 28:4961-4971. 2021
Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. 28:4645-4654. 2021
Quality of End-of-Life Cancer Care in Canada: A 12-Year Retrospective Analysis of Three Provinces’ Administrative Health Care Data Evaluating Changes over Time. 28:4673-4685. 2021
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. 28:4552-4576. 2021
The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer. 28:4392-4407. 2021
RELIEF: A Digital Health Tool for the Remote Self-Reporting of Symptoms in Patients with Cancer to Address Palliative Care Needs and Minimize Emergency Department Visits. 28:4273-4280. 2021
Assessment of Risk of Bias in Osteosarcoma and Ewing’s Sarcoma Randomized Controlled Trials: A Systematic Review. 28:3771-3794. 2021
The Surgical Management of Proximal Femoral Metastases: A Narrative Review. 28:3748-3757. 2021
Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy. 28:3683-3691. 2021
The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. 28:3649-3658. 2021
Virtual Care in Patients with Cancer: A Systematic Review. 28:3488-3506. 2021
What Matters in Cancer Survivorship Research? A Suite of Stakeholder-Relevant Outcomes. 28:3188-3200. 2021
Characterizing the Exercise Behaviour, Preferences, Barriers, and Facilitators of Cancer Survivors in a Rural Canadian Community: A Cross-Sectional Survey. 28:3172-3187. 2021
Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer. 28:3030-3040. 2021
Advancing Academic Cancer Clinical Trials Recruitment in Canada. 28:2830-2839. 2021
Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse. 28:2778-2788. 2021
Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease. 28:2731-2740. 2021
Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection. 28:2399-2408. 2021
Synovial Sarcoma: A Clinical Review. 28:1909-1920. 2021
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. 28:1847-1856. 2021
Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care. 28:1641-1651. 2021
Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario. 28:1376-1387. 2021
The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review. 28:1302-1313. 2021
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. 28:1256-1261. 2021
Restructuring Skin Cancer Care in Ontario: A Provincial Plan. 28:1183-1196. 2021
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data. 28:1153-1160. 2021
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. 28:1114-1124. 2021
Implementation of the Canadian National Standards in Breast Cancer Surgical Care: Gaps, Barriers, Enablers and Opportunities. 28:565-573. 2021
Identifying Best Implementation Practices for Smoking Cessation in Complex Cancer Settings. 28:471-484. 2021
National Thoracic Surgery Standards Implementation: Barriers, Enablers, and Opportunities. 28:405-416. 2021
Stereotactic Body Radiation Therapy (SBRT) for a Patient with a Myocardial Metastasis: A Case Report. 28:390-395. 2021
Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. 28:226-232. 2020
A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction. 28:184-195. 2020
Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events. 28:52-59. 2020
Code Status Communication Training in Postgraduate Oncology Programs: A Needs Assessment. 27:607-613. 2020
Code Status Communication Training in Postgraduate Oncology Programs: A Needs Assessment.. 27:607-613. 2020
First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma. 27:632-644. 2020
First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma.. 27:632-644. 2020
Implementing Changes to a Residency Program Curriculum before Competency-Based Medical Education: A Survey of Canadian Medical Oncology Program Directors. 27:614-620. 2020
Implementing Changes to a Residency Program Curriculum before Competency-Based Medical Education: A Survey of Canadian Medical Oncology Program Directors.. 27:614-620. 2020
Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations. 27:270-274. 2020
Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations.. 27:270-274. 2020
Improving Formative Assessments in Canadian Medical Oncology Residency Training. 27:524-525. 2020
Improving Formative Assessments in Canadian Medical Oncology Residency Training.. 27:524-525. 2020
Oncologists and Medical Assistance in Dying: Where Do We Stand? Results of a National Survey of Canadian Oncologists. 27:263-269. 2020
Oncologists and Medical Assistance in Dying: Where Do We Stand? Results of a National Survey of Canadian Oncologists.. 27:263-269. 2020
Age-Dependent Increased Odds of Cardiovascular Risk Factors in Cancer Survivors: Canadian Longitudinal Study on Aging Cohort. 27:368-376. 2020
Age-Dependent Increased Odds of Cardiovascular Risk Factors in Cancer Survivors: Canadian Longitudinal Study on Aging Cohort.. 27:368-376. 2020
Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. 27:204-214. 2020
Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma.. 27:204-214. 2020
Chest Wall Toxicity after Stereotactic Radiation in Early Lung Cancer: A Systematic Review. 27:179-189. 2020
Chest Wall Toxicity after Stereotactic Radiation in Early Lung Cancer: A Systematic Review.. 27:179-189. 2020
Real-World Treatment Patterns and Survival in Stage IV Non-Small-Cell Lung Cancer in Canada. 27:361-367. 2020
Retrospective Cohort Study of Unresectable Stage III Non-Small-Cell Lung Cancer in Canada. 27:354-360. 2020
Inflammatory Markers as Prognostic Factors of Recurrence in Advanced-Stage Squamous Cell Carcinoma of the Head and Neck. 27:135-141. 2020
A Catalyst for Transforming Health Systems and Person-Centred Care: Canadian National Position Statement on Patient-Reported Outcomes. 27:90-99. 2020
Baseline Staging Imaging for Distant Metastasis in Women with Stages I, II, and III Breast Cancer. 27:123-145. 2020
Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. 27:146-155. 2020
Immuno-Oncology—The New Paradigm of Lung Cancer Treatment. 27:78-86. 2020
Impact of COVID-19 on Canadian Medical Oncologists and Cancer Care: Canadian Association of Medical Oncologists Survey Report. 27:71-74. 2020
Nonsurgical Management of Advanced Hepatocellular Carcinoma: A Clinical Practice Guideline. 27:106-114. 2020
CanPROS Scientific Conference 2019 Oral Abstracts. 27:57-63. 2020
Complex Surgery and Perioperative Systemic Therapy for Genitourinary Cancer of the Retroperitoneum. 27:34-42. 2020
Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous or Mucosal Melanoma: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. 27:43-52. 2020
The Evolving Field of Bone Imaging in Multiple Myeloma: Is it Time to Abandon Skeletal Surveys?. 27:10-11. 2020
Trends in Survival Based on Treatment Modality in Patients with Pancreatic Cancer: A Population-Based Study. 27:1-8. 2020
Medullary Thyroid Cancer: An Introduction. 26:294-294. 2019
OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing. 26:618-623. 2019
Real-World Use of Trifluridine/Tipiracil for Patients with Metastatic Colorectal Cancer in Canada. 26:319-329. 2019
The Generation of Two Specific Cancer Costing Algorithms Using Ontario Administrative Databases. 26:682-692. 2019
An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction. 26:240-246. 2019
Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective. 26:551-557. 2019
Evolution of Adolescent and Young Adult Oncology in Canada. 26:228-233. 2019
Psychedelics for Psychological and Existential Distress in Palliative and Cancer Care. 26:225-226. 2019
Resource Use in the Last Three Months of Life by Lung Cancer Patients in Southern Ontario. 26:247-252. 2019
Incidence of Radionecrosis in Single-Fraction Radiosurgery Compared with Fractionated Radiotherapy in the Treatment of Brain Metastasis. 26:328-333. 2019
Initial Management of Small-Cell Lung Cancer (limited- and Extensive-Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy: A Systematic Review. 26:372-384. 2019
Position Statement on Defining and Standardizing an Oncoplastic Approach to Breast-Conserving Surgery in Canada. 26:405-409. 2019
Surgery after Chemoradiotherapy in Patients with Stage III (n2 or N3, Excluding T4) Non-Small-Cell Lung Cancer: A Systematic Review. 26:398-404. 2019
Cost-of-Illness Study for Non-Small-Cell Lung Cancer Using Real-World Data. 26:102-107. 2019
Establishing Funding Rates for Colonoscopy and Gastroscopy Procedures in Ontario. 26:98-101. 2019
Impact of a Novel Prioritization Framework on Clinician-Led Oncology Drug Submissions. 26:155-161. 2019
Surgical Attitudes toward Preoperative Breast Magnetic Resonance Imaging in Women with Early-Stage Breast Cancer. 26:194-201. 2019
Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. 26:81-93. 2019
Extended Venous Thromboembolism Prophylaxis after Abdominopelvic Cancer Surgery: A Retrospective Review. 26:106-110. 2019
Integrating Primary Care Providers through the Seasons of Survivorship. 26:48-54. 2019
A Little Help from My Friends: Social Support in Palliative Rehabilitation. 25:358-365. 2018
Moving Research Into Practice: Summary Report of the Ex/Cancer Meeting on Physical Activity, Exercise, and Rehabilitation in Oncology. 25:615-621. 2018
Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort. 25:384-392. 2018
Survival of Patients with Subglottic Squamous Cell Carcinoma. 25:569-575. 2018
Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. 25:317-328. 2018
Discrepancies Between Canadian Cancer Research Funding and Site-Specific Cancer Burden: A Spotlight on Ten Disease Sites. 25:338-341. 2018
Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites. 25:300-306. 2018
Neoadjuvant Therapy for Breast Cancer: Updates and Proceedings From the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer. 25:490-498. 2018
Predictors of Immunotherapy-Induced Immune-Related Adverse Events. 25:403-410. 2018
Treatment Algorithm in Cancer-Associated Thrombosis: Canadian Expert Consensus. 25:329-337. 2018
Anastomosing Hemangioma of the Kidney: Radiologic and Pathologic Distinctions of a Kidney Cancer Mimic. 25:220-223. 2018
Antiangiogenic Therapies in Non-Small-Cell Lung Cancer. 25:45-58. 2018
Clinical Practice Guidelines in Breast Cancer. 25:151-160. 2018
Comprehensive Metastatic Lung Cancer Care Must Include Palliative Care. 25:192-193. 2018
Connecting People with Cancer to Physical Activity and Exercise Programs: A Pathway to Create Accessibility and Engagement. 25:149-162. 2018
Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. 25:73-82. 2018
Feasibility of Assessing Patient Health Benefits and Incurred Costs Resulting from Early Dysphagia Intervention during and Immediately after Chemoradiotherapy for Head-and-Neck Cancer. 24:466-476. 2017
Identifying Barriers to Accrual in Radiation Oncology Randomized Trials. 24:524-530. 2017
Risk and Predictors of Suicide in Colorectal Cancer Patients: A Surveillance, Epidemiology, and End Results Analysis. 24:513-517. 2017
Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline. 24:540-546. 2017
The OncoSim Model: Development and Use for Better Decision-Making in Canadian Cancer Control. 24:401-406. 2017
Clinical Utility of Multigene Profiling Assays in Early-Stage Breast Cancer. 24:403-422. 2017
Staging and Surgical Approaches in Gastric Cancer: A Clinical Practice Guideline. 24:324-331. 2017
Training Oncoplastic Breast Surgeons: The Canadian Fellowship Experience. 24:394-402. 2017
Systemic Therapy in Incurable Gastroenteropancreatic Neuroendocrine Tumours: A Clinical Practice Guideline. 24:249-255. 2017
Current Practice in Total-Body Irradiation: Results of a Canada-Wide Survey. 24:181-186. 2017
Lessons Learned Implementing a Province-Wide Smoking Cessation Initiative in Ontario’s Cancer Centres. 24:185-190. 2017
Quality of Life for Patients Surviving Cancer: Are We Moving Ahead?. 24:151-152. 2017
Comparative Survival in Patients with Brain Metastases from Non-small-Cell Lung Cancer Treated before and after Implementation of Radiosurgery. 24:146-151. 2017
Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario. 24:103-110. 2017
Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. 24:111-119. 2017
Multigene Expression Profile Testing in Breast Cancer: Is There a Role for Family Physicians?. 24:95-102. 2017
Systemic Therapy in the Curative Treatment of Head-and-Neck Squamous Cell Cancer: Cancer Care Ontario Clinical Practice Guideline. 24:157-162. 2017
Uptake of a 21-Gene Expression Assay in Breast Cancer Practice: Views of Academic and Community-Based Oncologists. 24:138-145. 2017
Guideline for Radiotherapy with Curative Intent in Patients with Early-Stage Medically Inoperable Non-Small-Cell Lung Cancer. 24:44-49. 2017
Introducing Dr. Matthew Seftel. 24:7-7. 2017
Moving Guidelines into Action: A Report from Cancer Care Ontario’s Event Let’s Get Moving: Exercise and Rehabilitation for Cancer Patients. 24:65-74. 2017
Adjuvant Systemic Chemotherapy for Stages II and III Colon Cancer after Complete Resection: A Clinical Practice Guideline. 23:418-424. 2016
Early Palliative Care: Taking Ownership and Creating the Conditions. 23:367-370. 2016
Clinical Surveillance Compared with Clinical and Magnetic Resonance Imaging Surveillance for Brain Metastasis: A Feasibility Survey. 23:356-360. 2016
Follow-Up Care for Survivors of Lymphoma Who Have Received Curative-Intent Treatment. 23:499-513. 2016
Follow-Up of Patients Who Are Clinically Disease-Free after Primary Treatment for Fallopian Tube, Primary Peritoneal, or Epithelial Ovarian Cancer: A Program in Evidence-Based Care Guideline Adaptation. 23:343-350. 2016
Approach to Fever Assessment in Ambulatory Cancer Patients Receiving Chemotherapy: A Clinical Practice Guideline. 23:280-285. 2016
Fee-for-Service Cancer Rehabilitation Programs Improve Health-Related Quality of Life. 23:233-240. 2016
High-Grade Glioma Management and Response Assessment—Recent Advances and Current Challenges. 23:383-391. 2016
Plerixafor for Autologous Stem-Cell Mobilization and Transplantation for Patients in Ontario. 23:409-430. 2016
Approach to Biomarker Testing: Perspectives from Various Specialties. 23:178-183. 2016
Can the Referring Surgeon Enhance Accrual of Breast Cancer Patients to Medical and Radiation Oncology Trials? The Enhance Study. 23:276-279. 2016
Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. 23:196-200. 2016
Implementing Low-Dose Computed Tomography Screening for Lung Cancer in Canada: Implications of Alternative At-Risk Populations, Screening Frequency, and Duration. 23:179-187. 2016
Management of Small-Cell Lung Cancer with Radiotherapy—A Pan-Canadian Survey of Radiation Oncologists. 23:184-195. 2016
Accrual of Adolescents and Young Adults with Cancer to Clinical Trials. 23:81-85. 2016
Collaborative Case Conferences in Rectal Cancer: Case Series in a Tertiary Care Centre. 23:138-143. 2016
Follow-Up for Cervical Cancer: A Program in Evidence-Based Care Systematic Review and Clinical Practice Guideline Update. 23:109-118. 2016
Cost Trajectories for Cancer Patients. 23:64-75. 2016
Eastern Canadian Colorectal Cancer Consensus Conference 2013: Emerging Therapies in the Treatment of Pancreatic, Rectal, and Colorectal Cancers. 23:52-55. 2016
Temporal Association between Home Nursing and Hospital Costs at End of Life in Three Provinces. 23:42-51. 2016
A Population-Based Study of the Epidemiology of Pancreatic Cancer: A Brief Report. 22:478-484. 2015
Worth His Weight in .... 22:372-373. 2015
Are Patients Receiving the Right Care in the Right Place at the Right Time?. 22:315-316. 2015
Quality of End-of-Life Cancer Care in Canada: A Retrospective Four-Province Study Using Administrative Health Care Data. 22:341-355. 2015
An Open-Label Expanded-Access Trial of Bendamustine in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia: BEND-ACT. 22:260-271. 2015
Diagnosing Lung Cancer in the 21st Century: Are We Ready to Meet the Challenge of Individualized Care?. 22:272-278. 2015
The Optimal Organization of Gynecologic Oncology Services: A Systematic Review. 22:282-293. 2015
The Organization of Colposcopy Services in Ontario: Recommended Framework. 22:287-296. 2015
Views of Family Physicians about Survivorship Care Plans to Provide Breast Cancer Follow-Up Care: Exploration of Results from a Randomized Controlled Trial. 22:252-259. 2015
Systemic Therapy for Recurrent, Persistent, or Metastatic Cervical Cancer: A Clinical Practice Guideline. 22:211-219. 2015
Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-Small-Cell Lung Cancer: A Systematic Review. 22:183-215. 2015
Consensus Statement: The 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5–6, 2014. 22:113-123. 2015
Erratum: Tumour Inflammatory Response: Adding Fuel to the Fire?. 22:133-133. 2015
Secular Trends in the Survival of Patients with Laryngeal Carcinoma, 1995–2007. 22:85-99. 2015
A Canadian National Expert Consensus on Neoadjuvant Therapy for Breast Cancer: Linking Practice to Evidence and Beyond. 22:43-53. 2015
Adjuvant Chemotherapy for Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. 22:82-94. 2015
Adjuvant Endocrine Therapy for Early Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. 22:95-113. 2015
Locoregional Therapy of Locally Advanced Breast Cancer: A Clinical Practice Guideline. 22:54-66. 2015
Optimal Systemic Therapy for Early Breast Cancer in Women: A Clinical Practice Guideline. 22:67-81. 2015
Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline. 22:114-122. 2015
Clinical Challenges in Patients with Cancer-Associated Thrombosis: Canadian Expert Consensus Recommendations. 22:49-59. 2015
Safe Handling of Cytotoxics: Guideline Recommendations. 22:27-37. 2015
Tumour Inflammatory Response: Adding Fuel to the Fire?. 22:7-9. 2015
Health System Costs for Stage-Specific Breast Cancer: A Population-Based Approach. 21:281-293. 2014
A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults. 21:234-250. 2014
Implementing a Regional Oncology Information System: Approach and Lessons Learned. 21:224-233. 2014
Population-Based Utilization of Radiation Therapy by a Canadian Breast Cancer Cohort. 21:715-717. 2014
A Systematic Review of Active Treatment Options in Patients with Desmoid Tumours. 21:613-629. 2014
Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations. 21:573-603. 2014
Factors Associated with Publication of Randomized Phase iii Cancer Trials in Journals with a High Impact Factor. 21:564-572. 2014
Treatment and Follow-Up Strategies in Desmoid Tumours: A Practice Guideline. 21:642-649. 2014
Access to Personalized Medicine: Factors Influencing the Use and Value of Gene Expression Profiling in Breast Cancer Treatment. 21:426-433. 2014
Metastatic Renal Cell Carcinoma without Evidence of a Primary Renal Tumour. 21:521-524. 2014
Utilization of Stereotactic Ablative Radiotherapy in the Management of Oligometastatic Disease. 21:115-117. 2014
Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus. 21:265-309. 2014
Extracorporeal photopheresis in the management of graft-versus-host disease. 21:310-310. 2014
Patients’ Perceptions of Gene Expression Profiling in Breast Cancer Treatment Decisions. 21:203-211. 2014
Practice and Documentation of Palliative Sedation: A Quality Improvement Initiative. 21:100-103. 2014
Rasch analysis of the Edmonton Symptom Assessment System and research implications. 21:186-194. 2014
Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. 21:96-96. 2014
Oncology Education in Canadian Undergraduate and Postgraduate Medical Programs: A Survey of Educators and Learners. 21:75-88. 2014
Optimizing Outcomes with Azacitidine: Recommendations from Canadian Centres of Excellence. 21:44-50. 2014
A Prospective Evaluation of an Interdisciplinary Nutrition–Rehabilitation Program for Patients with Advanced Cancer. 20:310-318. 2013
An Interprofessional Palliative Care Oncology Rehabilitation Program: Effects on Function and Predictors of Program Completion. 20:301-309. 2013
Outcomes of her2-positive Early-Stage Breast Cancer in the Trastuzumab Era: A Population-Based Study of Canadian Patients. 20:539-545. 2013
The Association between Malnutrition and Psychological Distress in Patients with Advanced Head-and-Neck Cancer. 20:554-560. 2013
Chemotherapy (Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) in Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma: A Clinical Practice Guideline. 20:448-454. 2013
Canadian Integrative Oncology Research Priorities: Results of a Consensus-Building Process. 20:289-299. 2013
Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases. 20:300-306. 2013
A Comparison of Patient Knowledge of Clinical Trials and Trialist Priorities. 20:193-205. 2013
Liver Resection for Colorectal Cancer Metastases. 20:255-265. 2013
Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster Experience. 20:223-232. 2013
Surgical Margins and Handling of Soft-Tissue Sarcoma in Extremities: A Clinical Practice Guideline. 20:247-254. 2013
The growing pains of cancer survivors: a call for a paradigm of interdisciplinary care.. 20:e57-e58. 2013
Alignment of Practice Guidelines with Targeted-therapy Drug Funding Policies in Ontario. 20:21-33. 2013
Consensus Recommendations for Cancer Rehabilitation: Research and Education Priorities. 20:64-69. 2013
Improving Referral of Patients for Consideration of Adjuvant Chemotherapy after Surgical Resection of Lung Cancer. 19:422-427. 2012
Population-Based Home Care Services in Breast Cancer: Utilization and Costs. 19:383-391. 2012
Response to: What Is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer?. 19:502-502. 2012
Excision of the Primary Tumour in Patients with Metastatic Breast Cancer: A Clinical Dilemma. 19:270-279. 2012
Management of a Suspicious Adnexal Mass: A Clinical Practice Guideline. 19:244-257. 2012
Casting Stones and Casting Aspersions: Let’s Not Lose Sight of the Main Issues in the Euthanasia Debate. 19:139-142. 2012
Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study. 19:129-135. 2012
Fertility Risk Discussions in Young Patients Diagnosed with Colorectal Cancer. 19:155-159. 2012
The Importance of Multidisciplinary Team Management of Patients with Non-Small-Cell Lung Cancer. 19:7-15. 2012
What Is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer?. 19:60-66. 2012
A Call for Action in Survivorship Research and Care. 19:16-20. 2012
Fine-Needle Sspiration Biopsy versus Core-Needle Biopsy in Diagnosing Lung Cancer: A Systematic Review. 19:16-27. 2012
Role of Pemetrexed in Sdvanced Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Controlled Trials, with Histology Subgroup Analysis. 19:9-15. 2012
Extending Neoadjuvant Care through Multi-Disciplinary Collaboration: Proceedings from the Fourth Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer. 19:106-114. 2012
In This Issue of Current Oncology. 19:125-126. 2012
Corrigendum: Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. 18:303. 2011
Phenytoin Toxicity in a Patient Receiving 5-Fluorouracil–Based Chemotherapy for Metastatic Colorectal Cancer. 18:264-265. 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective (vol 18, S20, 2011). 18:303-303. 2011
Survivorship Services for Adult Cancer Populations: A Pan-Canadian Guideline. 18:265-281. 2011
Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. 18:303-303. 2011
Establishing a Multicentre Clinical Research Network: Lessons Learned. 18:243-249. 2011
Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. 18:S20-S27. 2011
Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer. 18:180-184. 2011
Prophylactic Feeding Tubes for Patients with Locally Advanced Head-and-Neck Cancer Undergoing Combined Chemotherapy and Radiotherapy—Systematic Review and Recommendations for Clinical Practice. 18:191-201. 2011
cml Biology for the Clinician in 2011: Six Impossible Things to Believe before Breakfast on the Way to Cure. 18:185-190. 2011
Legalizing Euthanasia or Assisted Suicide: The Illusion of Safeguards and Controls. 18:38-45. 2011
Phase II/III Study of Intraperitoneal Chemotherapy after Neoadjuvant Chemotherapy for Ovarian Cancer: NCIC CTG OV.21. 18:84-90. 2011
A Comparative Analysis of Monthly Out-of-Pocket Costs for Patients with Breast Cancer as Compared with Other Common Cancers in Ontario, Canada. 18:681-681. 2011
Terry Fox's legacy: a case for translational research. 17:262-263. 2010
Cancer Nutrition Rehabilitation Program: The Role of Social Work. 17:12-17. 2010
Terry Fox’s Legacy: A Case for Translational Research. 17:2-3. 2010
Current Management of Castrate-Resistant Prostate Cancer. 17:72-79. 2010
Ductal Carcinoma In Situ in a 25-Year-Old Man Presenting with Apparent Unilateral Gynecomastia. 17:133-137. 2010
Follow-Up for Women after Treatment for Cervical Cancer. 17:65-69. 2010
Estimating the National Wage Loss from Cancer in Canada. 17:40-49. 2010
Feasibility of Administering Zoledronic Acid in Palliative Patients Being Cared for in the Community: Results of a Pilot Study. 17:69-74. 2010
Cancer Diagnostic Assessment Programs: Standards for the Organization of Care in Ontario. 16:29-41. 2009
Clinician-patient communication: evidence-based recommendations to guide practice in cancer. 16:398-405. 2009
Clinician–Patient Communication: Evidence-Based Recommendations to Guide Practice in Cancer. 16:42-49. 2009
Generalizability of Toxicity Data from Oncology Clinical Trials to Clinical Practice: Toxicity of Irinotecan-Based Regimens in Patients with Metastatic Colorectal Cancer. 16:13-20. 2009
I-Tositumomab in lymphoma.. 16:32-47. 2009
Radiotherapy for Oncologic Emergencies on Weekends: Examining Reasons for Treatment and Patterns of Practice at a Canadian Cancer Centre. 16:55-60. 2009
Novel developments in angiogenesis cancer therapy. 16:191-195. 2009
Adjuvant and Neoadjuvant Small Molecule Targeted Therapy. 16:S60-S66. 2009
Hormone replacement therapy and outcome for women with non-small cell lung cancer: can an association be confirmed?. 16:21-25. 2009
Novel Developments in Angiogenesis Cancer Therapy. 16:50-54. 2009
Role of Cytokine Therapy for Renal Cell Carcinoma in the Era of Targeted Agents. 16:40-44. 2009
131I-tositumomab in lymphoma. 16:32-47. 2009
131I–Tositumomab in Lymphoma. 16:32-47. 2009
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. 16:S62-S68. 2009
The Role of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Therapy for Advanced, Metastatic, and Recurrent Non-Small-Cell Lung Cancer: A Canadian National Consensus Statement. 16:27-48. 2009
Chemotherapy-Induced Small Bowel Perforation in a Patient with Extrapulmonary Small-Cell Carcinoma of the Small Bowel. 15:298-301. 2008
The Colon Health and Life-Long Exercise Change (CHALLENGE) trial (CO.21). 15:279-285. 2008
The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. 15:262-270. 2008
Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group. 15:179-184. 2008
Healing and Survivorship: What Makes a Difference?. 15:185-187. 2008
How Do We Evaluate Outcome in an Integrative Oncology Program?. 15:78-82. 2008
Integrative Cancer Care in a US Academic Cancer Centre: The Memorial Sloan–Kettering Experience. 15:108-108. 2008
Integrative Oncology: A Canadian and International Perspective. 15:71-73. 2008
Integrative Oncology: A Canadian and International Perspective. 15:s71-s73. 2008
Research and Regulatory Issues for Integrative Oncology. 15:107-108. 2008
The Integrative Oncology Supplement—A Paradigm for Both Patient Care and Communication. 15:166-167. 2008
Cancer Nutrition and Rehabilitation—Its Time Has Come!. 15:117-122. 2008
The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake. 15:155-161. 2008
Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer. 15:9-23. 2008
Cancer Treatment–Related Bone Loss: A Review and Synthesis of the Literature. 15:30-40. 2008
Chemotherapy-induced small bowel perforation in a patient with extrapulmonary small-cell carcinoma of the small bowel. 15:44-47. 2008
Chinese Medicine and Biomodulation in Cancer Patients—Part One. 15:42-48. 2008
Chinese Medicine and Biomodulation in Cancer Patients—Part Two. 15:78-78. 2008
Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the National Cancer Institute of Canadia Clinical Trials Group. 15:14-19. 2008
Healing and survivorship: What makes a difference?. 15:20-22. 2008
Research and regulatory issues for integrative oncology. 15:S53-S63. 2008
The Colon Health and Life-Long Exercise Change trial: A randomized trial of the National Cancer Institute of Canada Clinical Trials Group. 15:8-16. 2008
The integrative oncology supplement - A paradigm for both patient care and communication. 15:1-2. 2008
Canadian Supportive Care Recommendations for the Management of Anemia in Patients with Cancer. 14:209-217. 2007
Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer. 14:195-208. 2007
Treatment of Depression in Cancer Patients. 14:180-188. 2007
Homeopathy for cancer?. 14:128-130. 2007
Homeopathy: Does a Teaspoon of Honey Help the Medicine Go Down?. 14:126-127. 2007
Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185. 14:154-161. 2007
Alemtuzumab in Chronic Lymphocytic Leukemia. 14:96-109. 2007
A Tale of Two Time Periods: Ovarian Cancer Trends in Ontario. 14:57-60. 2007
Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The National Cancer Institute of Canada Clinical Trials Group MY.11 Trial. 14:61-65. 2007
Massage Therapy for Cancer Patients: A Reciprocal Relationship between Body and Mind. 14:45-56. 2007
New Multidisciplinary Prostate Bone Metastases Clinic: First of Its Kind in Canada. 14:9-12. 2007
Radiofrequency Ablation and Cryoablation of Renal Tumours. 14:34-38. 2007
Cross-Border Referral for Early Breast Cancer: An Analysis of Radiation Fractionation Patterns. 13:124-129. 2006
Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer—A Systematic Review. 13:81-93. 2006
Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 2. 13:99-107. 2006
Promoting Best Gynecologic Oncology Practice: A Role For The Society of Gynecologic Oncologists of Canada. 13:94-98. 2006
Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.. 13:67-76. 2006
Natural Health Products That Inhibit Angiogenesis: A Potential Source for Investigational New Agents to Treat Cancer—Part 1. 13:14-26. 2006
Diffusion and dissemination of evidence-based dietary strategies for the prevention of cancer.. 4:13. 2005
Integrative oncology for comprehensive cancer centres: Definitions, scope, and policy. 12:103-117. 2005
Psychological, physical, social and economic impact of traveling great distances for cancer treatment. 12:1-7. 2005
Role of bisphosphonates in the management of skeletal complications in patients with multiple myeloma. 12:3-17. 2005
Should patients take or avoid antioxidant supplements during anticancer therapy? An evidence-based review. 12:44-54. 2005
Role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. 11:41-52. 2004
Thyroid function screening following radiation therapy for cancers of the head and neck: A survey of Canadian practice patterns. 11:68-71. 2004
Role of octreodite in the management of patients with cancer. 10:161-179. 2003
Use of gemcitabine in non-small-cell lung cancer. 10:3-26. 2003
Use of bisphosphonates in breast cancer metastatic to bone: Compliance with practice guidelines. 9:7-12. 2002
Accelerated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. 8:16-27. 2001
Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck. 8:6-15. 2001
The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer. 8:50-59. 2001
Treatment of locally advanced squamous cell carcinoma of the head and neck: A summary and overview. 8:3-5. 2001
Use of irinotecan combined with 5-fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer. 8:60-68. 2001
Altered fractionation of radical radiaton therapy in the management of unresectable non-small-cell lung cancer. 7:98-109. 2000
Drug therapy for chronic myeloid leukaemia. 7:229-241. 2000
Optimum radiation fractionation for T1 N0 glottic carcinoma. 7:91-97. 2000
The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer. 7:162-172. 2000
The use of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer and methods of assessing HER2/neu status - An evidence summary. 7:242-251. 2000
Use of capecitabine in stage IV breast cancer: An evidence summary. 7:84-90. 2000
Use of irinotecan in secondline treatment of metastatic colorectal carcinoma. 7:29-36. 2000
Use of topotecan in pre-treated recurrent or relapsed ovarian cancer patients. 7:136-148. 2000
Use of vinorelbine in stage IV breast cancer: An evidence summary. 7:24-28. 2000
Humanised antibodies for cancer therapy. Part 2: Review of clinical trials with rituximab and trastuzumab. 6:131-137. 1999
Humanized antibodies for cancer therapy. Part 1: Humanizing mouse antibodies. 6:74-77. 1999
Predictors of intention to act: High-school students and cervical screening. 6:36-42. 1999
The role of adjuvant systemic therapy in node-negative breast cancer. 6:78-89. 1999
The role of fludarabine in intermediate- and high-risk chronic lymphocytic leukaemia. 6:90-102. 1999
Use of biphosphonates in patients with bone metastases from breast cancer. 6:144-154. 1999
Use of rituximab in the treatment of lymphoma: An evidence summary. 6:228-235. 1999
Bisphosphonates for bone metastases in breast cancer patients: Trial design issues and evaluation of published studies. 5:181-187. 1998
Bone metastases: A review of their pathogenesis. 5:114-118. 1998
A call for action in survivorship research and care. 19:16-20.
Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective. 18:303-303.
Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review. 19:16-27.
Homeopathy, Fundamentalism, and the Memory of Water. 14:221-223.
Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. 19:9-15.

Current Oncology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)